{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:51:49Z","timestamp":1792007509605,"version":"4.4.0"},"reference-count":43,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>The aim of this systematic review is to provide a comprehensive overview of the existing literature, comparing 18F-fluorodeoxyglucose (FDG) and 11C-methionine (MET) for the imaging of multiple myeloma (MM) with positron emission computed tomography (PET\/CT). Relevant studies published from 2013 up to March 2023 were selected by searching Scopus, PubMed, and Web of Science. Selected imaging studies were analyzed using a modified version of the critical Appraisal Skills Programme (CASP). Ten studies encompassing 335 patients were selected. On a patient-based analysis, MET sensitivity ranged between 75.6% and 100%, resulting higher than that measured for FDG (0\u2013100%). MET outperformed FDG for the detection of focal lesions, diffuse bone marrow involvement and mixed patterns. PET-derived parameters resulted higher for MET than for FDG, with a strong correlation with clinical variables (e.g., monoclonal component and beta-2-microglobulin levels, bone marrow infiltration, etc.), although FDG maintained a prognostic impact on outcome prediction. When compared to other tracers or imaging modalities, MET showed stronger correlation and inter-observer agreement than FDG. Although biased by the small cohorts and requiring confirmation through multicenter studies, preliminary findings suggest that MET\u2013PET should be preferred to FDG for PET imaging of MM, or alternatively used as a complementary imaging modality. Some issues, such as tracer availability and the role of MET with respect to other emerging tracers (i.e., 68Ga-pentixafor, 18F-FACBC and 18F-FET), should be the topic of further investigations.<\/jats:p>","DOI":"10.3390\/diagnostics13122009","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T01:32:34Z","timestamp":1686274354000},"page":"2009","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Head-to-Head Comparison between FDG and 11C-Methionine in Multiple Myeloma: A Systematic Review"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4423-5496","authenticated-orcid":false,"given":"Luca","family":"Filippi","sequence":"first","affiliation":[{"name":"Nuclear Medicine Unit, \u201cSanta Maria Goretti\u201d Hospital, Via Antonio Canova, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3497-4236","authenticated-orcid":false,"given":"Viviana","family":"Frantellizzi","sequence":"additional","affiliation":[{"name":"Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza, University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bartoletti","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Department of Medicine (DIMED), University of Padua, Via Giustiniani, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4690-1528","authenticated-orcid":false,"given":"Giuseppe De","family":"Vincentis","sequence":"additional","affiliation":[{"name":"Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza, University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Schillaci","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University Tor Vergata, Viale Oxford 81, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5955-9488","authenticated-orcid":false,"given":"Laura","family":"Evangelista","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy"},{"name":"IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Padala, S.A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., and Ajebo, G.H. (2021). Epidemiology, Staging, and Management of Multiple Myeloma. Med. Sci., 9.","DOI":"10.3390\/medsci9010003"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1126\/science.1164390","article-title":"Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells","volume":"322","author":"Colmone","year":"2008","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Eisfeld, C., Kaj\u00fcter, H., M\u00f6ller, L., Wellmann, I., Shumilov, E., and Stang, A. (2023). Time trends in survival and causes of death in multiple myeloma: A population-based study from Germany. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10787-5"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/leu.2009.61","article-title":"Is the international staging system superior to the Durie\u2013Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant","volume":"23","author":"Hari","year":"2009","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2214\/AJR.21.25878","article-title":"Updates and Ongoing Challenges in Imaging of Multiple Myeloma: AJR Expert Panel Narrative Review","volume":"217","author":"Wu","year":"2021","journal-title":"Am. J. Roentgenol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Nanni, C. (2020). PET-FDG: Impetus. Cancers, 12.","DOI":"10.3390\/cancers12041030"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2214\/ajr.184.4.01841199","article-title":"Value of FDG PET in the Assessment of Patients with Multiple Myeloma","volume":"184","author":"Bredella","year":"2005","journal-title":"Am. J. Roentgenol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Mesguich, C., Hulin, C., Lascaux, A., Bordenave, L., Marit, G., and Hindi\u00e9, E. (2020). Choline PET\/CT in Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12061394"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"622501","DOI":"10.3389\/fonc.2020.622501","article-title":"PET\/CT in Multiple Myeloma: Beyond FDG","volume":"10","author":"Matteucci","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/cas.12529","article-title":"Expression of L-type amino acid transporter 1 (LAT 1) as a prognostic and therapeutic indicator in multiple myeloma","volume":"105","author":"Isoda","year":"2014","journal-title":"Cancer Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/17474086.2014.873347","article-title":"The utility of newer imaging techniques as predictors of clinical outcomes in multiple myeloma","volume":"7","author":"Brioli","year":"2014","journal-title":"Expert Rev. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s00259-012-2333-3","article-title":"Clinical value of 11C-methionine PET\/CT in patients with plasma cell malignancy: Comparison with 18F-FDG PET\/CT","volume":"40","author":"Nakamoto","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12149-014-0931-9","article-title":"Comparison of 11C-4\u2032-thiothymidine, 11C-methionine, and 18F-FDG PET\/CT for the detection of active lesions of multiple myeloma","volume":"29","author":"Okasaki","year":"2015","journal-title":"Ann. Nucl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7150\/thno.13921","article-title":"11 C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement","volume":"6","author":"Lapa","year":"2016","journal-title":"Theranostics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.7150\/thno.20491","article-title":"11 C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2967\/jnumed.118.217539","article-title":"Hexokinase-2 Expression in 11 C-Methionine\u2013Positive, 18 F-FDG\u2013Negative Multiple Myeloma","volume":"60","author":"Kircher","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhou, X., Dierks, A., Kertels, O., Kircher, M., Schirbel, A., Samnick, S., Buck, A.K., Knorz, S., B\u00f6ckle, D., and Scheller, L. (2020). 18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET\/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features. Cancers, 12.","DOI":"10.3390\/cancers12082333"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Morales-Lozano, M.I., Viering, O., Samnick, S., Rodriguez-Otero, P., Buck, A.K., Marcos-Jubilar, M., Rasche, L., Prieto, E., Kort\u00fcm, K.M., and San-Miguel, J. (2020). 18F-FDG and 11C-Methionine PET\/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers. Cancers, 12.","DOI":"10.3390\/cancers12041042"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"110493","DOI":"10.1016\/j.ejrad.2022.110493","article-title":"Multi-parametric whole-body MRI evaluation discerns vital from non-vital multiple myeloma lesions as validated by 18F-FDG and 11C-methionine PET\/CT","volume":"155","author":"Heidemeier","year":"2022","journal-title":"Eur. J. Radiol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Morales-Lozano, M.I., Rodriguez-Otero, P., Sancho, L., Nu\u00f1ez-Cordoba, J.M., Prieto, E., Marcos-Jubilar, M., Rosales, J.J., Alfonso, A., Guillen, E.F., and San-Miguel, J. (2022). 11C-Methionine PET\/CT in Assessment of Multiple Myeloma Patients: Comparison to 18F-FDG PET\/CT and Prognostic Value. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179895"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2214\/AJR.22.28560","article-title":"Carbon-11-Labeled Methionine PET\/CT in Patients with FDG-Occult Multiple Myeloma: A Prospective Pilot Study","volume":"220","author":"Wang","year":"2023","journal-title":"Am. J. Roentgenol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MNM.0b013e32833c42ef","article-title":"Imaging with 11Carbon labelled PET tracers","volume":"31","author":"Fanti","year":"2010","journal-title":"Nucl. Med. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/17434440.2022.2117612","article-title":"Digital PET\/CT with 18F-FACBC in early castration-resistant prostate cancer: Our preliminary results","volume":"19","author":"Filippi","year":"2022","journal-title":"Expert Rev. Med. Devices"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s11307-022-01734-0","article-title":"Comparison of [18F]fluciclovine and [18F]FDG PET\/CT in Newly Diagnosed Multiple Myeloma Patients","volume":"24","author":"Stokke","year":"2022","journal-title":"Mol. Imaging Biol."},{"key":"ref_27","first-page":"23","article-title":"18F-fluoro-ethyl-tyrosine (18F-FET) PET\/CT as a potential new diagnostic tool in multiple myeloma: A preliminary study","volume":"23","author":"Jurczyszyn","year":"2019","journal-title":"Contemp. Oncol. Poznan Pol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00259-016-3502-6","article-title":"Treatment response evaluation with 18F-FDG PET\/CT and 18F-NaF PET\/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation","volume":"44","author":"Sachpekidis","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zhou, X., Dierks, A., Kertels, O., Samnick, S., Kircher, M., Buck, A.K., Haertle, L., Knorz, S., B\u00f6ckle, D., and Scheller, L. (2020). The Link between Cytogenetics\/Genomics and Imaging Patterns of Relapse and Progression in Patients with Relapsed\/Refractory Multiple Myeloma: A Pilot Study Utilizing 18F-FDG PET\/CT. Cancers, 12.","DOI":"10.3390\/cancers12092399"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e13170","DOI":"10.1111\/jne.13170","article-title":"Volumetric parameters from [18F] FDG PET \/ CT predicts survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"34","author":"Aly","year":"2022","journal-title":"J. Neuroendocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13550-023-00960-z","article-title":"The potential application of MR-derived ADCmin values from 68Ga-DOTATATE and 18F-FDG dual tracer PET\/MR as replacements for FDG PET in assessment of grade and stage of pancreatic neuroendocrine tumors","volume":"13","author":"Gao","year":"2023","journal-title":"EJNMMI Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3892\/or.2013.2886","article-title":"Molecular mechanisms of [18F]fluorodeoxyglucose accumulation in liver cancer","volume":"31","author":"Izuishi","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Chiaravalloti, A., Filippi, L., Ricci, M., Cimini, A., and Schillaci, O. (2019). Molecular Imaging in Pediatric Brain Tumors. Cancers, 11.","DOI":"10.3390\/cancers11121853"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Urso, L., Panareo, S., Castello, A., Ambrosio, M.R., Zatelli, M.C., Caracciolo, M., Tonini, E., Valpiani, G., Boschi, A., and Uccelli, L. (2022). Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu\/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14102009"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/14737159.2023.2192351","article-title":"Radiomics and theranostics with molecular and metabolic probes in prostate cancer: Toward a personalized approach","volume":"23","author":"Filippi","year":"2023","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Urso, L., Frantellizzi, V., De Vincentis, G., Schillaci, O., Filippi, L., and Evangelista, L. (2023). Clinical applications of long axial field-of-view PET\/CT scanners in oncology. Clin. Transl. Imaging.","DOI":"10.1007\/s40336-023-00547-7"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/jmri.26848","article-title":"MRI and PET\/MRI in hematologic malignancies","volume":"51","author":"Mayerhoefer","year":"2020","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1007\/s00330-021-08529-x","article-title":"Diagnostic Accuracy of 2-[18F]FDG-PET and whole-body DW-MRI for the detection of bone marrow metastases in children and young adults","volume":"32","author":"Rashidi","year":"2022","journal-title":"Eur. Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.118.220665","article-title":"Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine","volume":"61","author":"Solnes","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Cimini, A., Ricci, M., Chiaravalloti, A., Filippi, L., and Schillaci, O. (2020). Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113849"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/17434440.2020.1796633","article-title":"Aptamer-based technology for radionuclide targeted imaging and therapy: A promising weapon against cancer","volume":"17","author":"Filippi","year":"2020","journal-title":"Expert Rev. Med. Devices"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2174\/1389557523666221216095821","article-title":"Nuclear Medicine Application of Pentixafor\/Pentixather Targeting CXCR4for Imaging and Therapy in Related Disease","volume":"23","author":"Chen","year":"2023","journal-title":"Mini-Rev. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Wang, M., Zhang, J., Liu, L., Wang, J., and Zhang, C. (2023). The role of 68Ga-Pentixafor PET in multiple myeloma. Clin. Transl. Imaging.","DOI":"10.1007\/s40336-023-00573-5"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/12\/2009\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:51:21Z","timestamp":1760125881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/12\/2009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":43,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["diagnostics13122009"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics13122009","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]}}}